Autolus Therapeutics AUTL 深 沪
等待开盘 09-16 09:30:00 美东时间
1.32
-0.060
-4.35%
华盛通- 最 高1.4186
- 今 开1.40
- 成交量 400.83万股
- 最 低 1.295
- 昨 收 1.38
- 总市值 3.51亿
- 52周最高 5.00
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 1.105
- 委 比 -0.42%
- 总股本 2.66亿
- 历史最高 53.24
- 量 比 0.65
- 振 幅 8.96%
- 历史最低 1.105
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $5
Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target from $6 to $5.
08-13 20:50
Autolus Therapeutics shares are trading lower. The company reported Q2 financial results.
Autolus Therapeutics shares are trading lower. The company reported Q2 financia...
08-13 00:56
Autolus Therapeutics Q2 EPS $(0.18) Beats $(0.24) Estimate, Sales $20.923M Beat $12.905M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 18.18 percent increase over losses of $(0.22) per share from
08-12 19:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Autolus Therapeutics (Nasdaq: AUTL) will release its Q2 2025 financial results and operational highlights on August 12, 2025. A conference call at 8:30am EDT will discuss the results, with registration via the provided link. A webcast and replay will also be available on their website. The company focuses on developing next-generation T cell therapies for cancer and autoimmune diseases, with a marketed therapy, AUCATZYL®, and a pipeline of produc...
07-24 11:30
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
07-21 21:59
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
The European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The approval is based on the FELIX clinical trial, which showed a 76.6% complete response rate, a median response duration of 21.2 months, and low toxicity. The therapy involves CD19-targeted CAR T cells with a fast off-rate design. AUCATZYL is al...
07-21 11:00
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics授予60名员工总计360,550股股票期权，行使价为$2.47，期权有效期为10年，分四年归属，第一年归属25%，剩余部分每月归属，需员工持续服务。公司简介：Autolus是一家早期商业化阶段的生物制药公司，利用T细胞编程技术开发下一代T细胞疗法，用于治疗癌症和自身免疫疾病，已有已上市疗法AUCATZYL，并有多款候选产品在研。
07-15 20:05
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
06-30 20:36
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
